BioLineRx Ltd. BLRX

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.2M$28.9M$4.8M$0$0—————
Operating income -$10.3M-$20.4M-$49.7M-$29.2M-$24.8M-$22.9M-$28.1M-$25.6M-$25.2M-$16.5M
Net income -$2.0M-$9.2M-$60.6M-$25.0M-$27.1M-$30.0M-$25.4M-$23.0M-$24.4M-$15.8M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets $40.9M$38.9M$63.9M$76.4M$81.4M$47.3M$53.6M$56.2M$61.0M$38.9M
Total equity $23.3M$13.5M$13.2M$50.8M$68.1M$22.0M$33.4M$41.3M$52.9M$35.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001178913-26-001807.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -75M -50M -25M 0 25M 50M Net income, FY2016: -15.8M Net income, FY2017: -24.4M Net income, FY2018: -23M Net income, FY2019: -25.4M Net income, FY2020: -30M Revenue, FY2021: 0 Net income, FY2021: -27.1M Revenue, FY2022: 0 Net income, FY2022: -25M Revenue, FY2023: 4.8M Net income, FY2023: -60.6M Revenue, FY2024: 28.9M Net income, FY2024: -9.2M Revenue, FY2025: 1.2M Net income, FY2025: -2M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — $0 $0 $4.8M $28.9M $1.2M
Gross profit — — — — — — — — — —
Net income -$15.8M -$24.4M -$23.0M -$25.4M -$30.0M -$27.1M -$25.0M -$60.6M -$9.2M -$2.0M

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%